Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in p53-Mutated Refractory Solid Tumors
NCT04869475Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in solid tumor, sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04869475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04869475.